ICH consults on format for periodic benefit-risk reporting for marketed drugs
This article was originally published in SRA
The International Conference on Harmonisation has issued for stakeholder consultation a common standard for the periodic reporting by drug companies of the benefit-risk profile of their marketed products, including approved drugs that are under further study1,2.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.